Creating a Global Company

Sales Breakup Q3 & 9m FY22 SUN PHARMA (All Figures in Rs. Mn) Q3 FY22 Q3 FY21 CHANGE 9m FY22 9m FY21 CHANGE Formulation India 31,676 27,528 15.1% 96,637 76,724 26.0% US 29,718 27,629 7.6% 84,491 73,933 14.3% Emerging Markets 17,899 15,073 18.8% 51,957 43,825 18.6% ROW# 13,532 12,991 4.2% 41,138 36,788 11.8% Sub-total 92,824 83,220 11.5% 274,223 231,269 18.6% ΑΡΙ 4,710 4,505 4.6% 14,218 15,147 -6.1% Others 608 363 67.4% 1,963 1,278 53.6% Gross Sales 98,142 88,088 11.4% 290,403 247,693 17.2% US Formulations India Branded Generics Emerging Markets Rest of World API & Others 18% 31% 17% 32% Q3 Q3 FY22 14% FY21 15% 6% 6% 30% 31% # Includes Western Europe, Canada, Japan, Australia, New Zealand and other markets 51

View entire presentation